Lupus
Erythema scores for cutaneous lupus trial eligibility limit skin of color representation
Requiring erythema alone for entry into cutaneous lupus erythematosus trials may exclude patients with skin of color and increase health disparities, according to a study.
Cutaneous lupus erythematosus associated with cardiovascular disease
Patients with cutaneous lupus erythematosus may be at an increased risk for atherosclerotic cardiovascular disease, even more than those with psoriasis, according to a study.
Uptake of Benlysta, Saphnelo signal ‘exciting time’ for ‘lupologists’
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.
CAR T therapy for autoimmune disease exploded in 2024. Here’s what you may have missed
After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor T-cell therapies for autoimmune rheumatic diseases.
Elsubrutinib, upadacitinib combination lowers lupus activity through 104 weeks
WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely active systemic lupus erythematosus, according to data presented at ACR Convergence 2024.
Patients with lupus, type 2 diabetes at lower risk for MACE, VTE with GLP-1 vs DPP4 drugs
WASHINGTON — Patients with lupus and type 2 diabetes who receive glucagon-like peptide-1 receptor agonists demonstrate a lower risk for cardiac events and kidney disease progression vs. dipeptidyl peptidase 4 inhibitors, according to data.
CAR T therapy shows ‘no major hematotoxicites’ in autoimmune disease phase 1/2 study
WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.
CD19 CAR-T therapy yields long-term benefits in lupus, myositis, systemic sclerosis
WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.
CAR-NK cell approach achieves ‘efficacy, persistence and super safety’ in lupus
WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super safety” in a small cohort of patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2024.
ACR recommends triple therapy for lupus nephritis in new 2024 guidelines
WASHINGTON — Early triple therapy may be the most effective strategy for lupus nephritis, according to the new 2024 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis.